Medtronic Reports Strong Q3 FY26 Results, Exceeding Revenue and EPS Guidance with Key Product Launches
MDT sits 28% above its 52-week low of $79.55.
Summary
Medtronic plc announced strong third quarter fiscal year 2026 financial results, exceeding revenue and non-GAAP EPS guidance, driven by robust growth in key portfolios and significant product approvals.
Key Events · Earnings and Guidance · MDT
-
Exceeded Q3 FY26 Financial Guidance
Medtronic reported Q3 revenue of $9.017 billion, an 8.7% reported increase and 6.0% organic growth, exceeding guidance by 50 basis points. Non-GAAP diluted EPS of $1.36 was three cents ahead of the guidance mid-point.
-
Strong Growth in Cardiovascular Portfolio
The Cardiovascular Portfolio revenue increased 10.6% organically, with Cardiac Ablation Solutions growing 80% year-over-year, including 137% in the U.S., driven by its pulsed field ablation portfolio.
-
Key Product Approvals and Launches
The company secured CE Mark for Sphere-360™ and initiated its U.S. pivotal trial, along with U.S. FDA clearances for the Hugo™ robotic-assisted surgery system and Stealth AXiS™ Surgical System for spinal procedures.
-
Diabetes Business Shows Robust International Growth
Diabetes revenue increased 8.3% organically, primarily fueled by double-digit strength in international markets.
Analysis · MDT · Industrial Applications And Services
Medtronic plc delivered a strong third quarter, surpassing both revenue and non-GAAP EPS guidance. The company's 6.0% organic revenue growth, coupled with an 8.7% reported increase to $9.017 billion, demonstrates robust operational performance. Key drivers include exceptional growth in the Cardiovascular portfolio, particularly Cardiac Ablation Solutions, which surged 80% year-over-year. Significant regulatory milestones, such as U.S. FDA clearance for the Hugo™ robotic-assisted surgery system and Stealth AXiS™ Surgical System, alongside a CE Mark for Sphere-360™, highlight a strong innovation pipeline. The reaffirmation of full-year FY26 organic revenue and non-GAAP EPS guidance, despite the strong Q3 beat, suggests management's confidence in sustained performance. This filing indicates positive momentum for Medtronic, driven by strategic investments in high-growth opportunities and successful product commercialization.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 41.4% of the 1207 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDT was trading at $102.22 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $127.5B. The 52-week trading range was $79.55 to $106.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.